Health Canada warns of bacterial contamination in unauthorized peptides sold online: what hormone patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

---

Health Canada seized more than 11,400 vials of unauthorized injectable peptides from Shanghai ERP Peptide Biotechnology Co. Ltd. (ERP Peptide) and two Canadian online retailers in early November 2026, after laboratory testing identified three distinct bacteria capable of causing serious harm in humans. Several of the contaminated products, including Human Chorionic Gonadotropin (HCG) and Tesamorelin, are compounds that hormone-care patients in Canada sometimes seek outside the regulated system, often because of cost, wait times, or limited clinic access. If you have purchased any peptide product online from an unverified source, Health Canada's position is unambiguous: stop using it now.

For hormone patients in Canada specifically, this seizure matters because the affected product list overlaps directly with compounds used or sought in fertility support, HIV-related lipodystrophy treatment, and off-label anti-aging or body-composition protocols. HCG, for example, is used in some fertility and testosterone-support regimens. Tesamorelin (sold in Canada as Egrifta, manufactured by Theratechnologies) is Health Canada-approved for HIV-associated lipodystrophy but is sometimes obtained without a prescription through grey-market channels. Tirzepatide (sold in the US as Mounjaro and Zepbound; approved by Health Canada as Mounjaro for type 2 diabetes) also appeared on the seized product list. None of the ERP Peptide versions of these compounds have been assessed by Health Canada for safety, efficacy, or sterility.

What this means in Canada

In Canada, injectable peptides are regulated as prescription drugs under the Food and Drugs Act. That means they require a licensed prescriber, a licensed pharmacy, and a product that has passed Health Canada's review process. ERP Peptide's products had none of that. Health Canada has confirmed it is working with the Canada Border Services Agency to intercept further unauthorized shipments from entering the country, and has formally requested ERP Peptide cease selling into the Canadian market.

For patients wondering about coverage: legitimate, Health Canada-approved versions of some peptide-class drugs do exist on provincial formularies. Tesamorelin (Egrifta) is covered under some provincial exceptional-access programs for eligible HIV patients. Tirzepatide (Mounjaro) has limited provincial pharmacare coverage as of late 2026, varying by province. OHIP in Ontario does not cover most peptide therapies for off-label indications. RAMQ in Quebec and MSP in British Columbia similarly restrict coverage to approved indications. Patients seeking these drugs for weight loss, muscle growth, or anti-aging will generally not find provincial coverage and should be especially cautious about where they source them.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a specific position statement on peptide therapy for hormone-care patients as of this writing. The Canadian Medical Association, however, flagged unauthorized peptide marketing as a pressing concern in an April 2026 segment aired on Global News, noting the difficulty patients face distinguishing legitimate compounding pharmacies from grey-market online sellers.

What changed

The November 2026 seizure is the largest single peptide enforcement action Health Canada has publicly disclosed. The three bacteria found during testing have not been named by Health Canada in its public advisory, but the agency stated they are harmful to humans. Beyond bacterial contamination, Health Canada's testing of unauthorized peptides has previously found products containing too little or too much active ingredient, heavy metals, glass and plastic particles, unknown solvents, and compounds that trigger allergic reactions or dangerous drug interactions.

The risks Health Canada lists for unauthorized peptide use include hormonal imbalance, mood changes, blood sugar dysregulation, liver or kidney damage, blood clots, and growth of cancerous tumours. These are not theoretical. Injecting a bacterially contaminated solution carries the immediate risk of local infection, abscess, septicemia, and, in severe cases, septic shock.

The US context is relevant here: in late 2026, US Health and Human Services Secretary RFK Jr. moved to loosen restrictions on unapproved peptides in the United States, a policy shift that has no parallel in Canada. Health Canada has not signalled any intention to relax its regulatory framework for injectable peptides.

What Canadian patients should know

If you have purchased injectable peptides online, particularly from any retailer that sourced from ERP Peptide or from Chinese suppliers more broadly, stop using the product. Do not attempt to finish a vial on the assumption that you feel fine so far. Bacterial contamination is not visible and does not always produce immediate symptoms.

If you develop a fever, chills, redness, pain, or swelling at an injection site after using any unauthorized injectable product, go to an emergency department or call 811 (Health Link in Alberta, Telehealth Ontario, or your provincial nurse line) immediately. Tell the clinician what you injected and when.

For patients who want access to peptide-class therapies through legitimate channels, options in Canada include family physicians, endocrinologists, and a growing number of regulated telehealth platforms. Felix (a Canadian men's and general health platform), Cleo (a Canadian women's health platform), Maple, and Telus Health all operate within the Canadian regulatory framework and can connect patients with licensed prescribers. Science and Humans (scienceandhumans.com) is a Canadian platform that offers physician-supervised hormone and metabolic care. None of these platforms can legally prescribe or dispense unauthorized compounds, which is precisely the point: a prescription from a Canadian licensed provider, filled at a licensed Canadian pharmacy, is the only route to a product that has been verified for sterility and correct dosing.

Compounding pharmacies in Canada can legally prepare some peptide formulations under specific conditions, but they must be licensed by their provincial pharmacy college and operate under Health Canada's oversight framework. If a compounding pharmacy is selling injectable peptides without requiring a prescription, that is a regulatory violation.

Limitations and open questions

Health Canada has not publicly named the three bacteria found in ERP Peptide's products, which makes it difficult for clinicians to assess the specific infection risk for patients who have already used them. The agency has also not released a full list of the online retailers involved in the seizure beyond stating that two retailers sold ERP Peptide products.

The SOGC has not issued guidance on peptide therapy for perimenopausal or menopausal hormone care, a gap that leaves clinicians without a formal Canadian society position when patients ask about compounds like MOTS-C or NAD+ for hormone-adjacent wellness purposes. Whether those compounds have any validated clinical benefit in hormone care remains an open research question. CIHR (Canadian Institutes of Health Research) has not funded large-scale trials on most of the peptides in the ERP Peptide product list.

Finally, the enforcement action addresses supply, not demand. As long as patients face barriers to accessing legitimate hormone care, including long wait times for endocrinology referrals and limited pharmacare coverage for approved therapies, some will continue to seek unauthorized alternatives. That is a system problem Health Canada's seizure does not solve.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.